India's CDMO Sector Poised for Growth as Pharma Diversifies Away from China
The global pharmaceutical supply chain is undergoing a structural realignment as multinational companies seek to reduce their dependence on China. As regulatory scrutiny intensifies around Chinese giants like WuXi AppTec, Indian Contract Development and Manufacturing Organisations (CDMOs) are emerging as the primary beneficiaries of this strategic shift.
India Emerges as the Preferred Global Alternative
The movement away from China-centric manufacturing is not a sudden reaction but a trend that began nearly two years ago. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, global pharmaceutical companies have already initiated conversations to diversify their manufacturing footprints. The inclusion of Indian entities in regulatory frameworks like the 1260H list has further accelerated this transition, providing much-needed clarity for global drugmakers.
The shift is characterized by a move from clinical-stage support to large-scale commercial manufacturing. While many companies previously utilized India primarily for clinical supplies, there is a growing trend of utilizing Indian CDMOs for commercial-scale production. This is evidenced by the increasing number of Phase III and pre-registration molecules being handled by Indian players.
Sai Life Sciences: Scaling Capacity to Meet Demand
To capitalize on this landmark opportunity, Sai Life Sciences has announced a massive capacity expansion plan. The company intends to invest between ₹1,100 crore and ₹1,300 crore by FY27. This capital expenditure will be funded through a combination of internal accruals and debt, a move made possible by the company's current healthy balance sheet, which carries minimal to no debt.
While the investment is significant, management notes that the impact on revenue will be gradual. The pharmaceutical industry is heavily regulated, meaning the transfer of products and manufacturing contracts requires extensive regulatory approvals and lengthy timelines. Consequently, Sai Life Sciences has maintained its revenue growth guidance at a steady 15-20% CAGR.
A Structural Shift in Revenue Mix
The changing landscape of the industry is clearly reflected in the revenue profiles of leading Indian CDMOs. At Sai Life Sciences, the contribution from global "Big Pharma" has nearly doubled over the last four years, rising from 28% to 49% of the total revenue mix. This highlights a deeper integration of Indian manufacturers into the long-term supply chains of the world's largest drug innovators.
The company expects the second half of the current financial year to be stronger than the first, driven by new capacity coming online and improved order visibility. As production facilities become operational, the focus will shift toward reaching optimal capacity utilization to serve the growing pipeline of commercial molecules.
Key Takeaways
- Strategic Diversification: Global pharma companies are actively moving manufacturing away from China toward India to mitigate regulatory and supply chain risks.
- Aggressive Capex: Leading Indian CDMOs, such as Sai Life Sciences, are investing up to ₹1,300 crore to expand capacity to meet rising global demand.
- Commercial Shift: The Indian CDMO sector is evolving from a provider of clinical trial supplies to a critical partner for large-scale commercial drug manufacturing.